Retatrutide: A Triple-Agonist Breakthrough Transforming Metabolic Research

Retatrutide has captured scientific interest as a next-generation, multi-receptor agonist designed to target the core drivers of metabolic disease. Unlike single-pathway approaches, this engineered peptide engages three key metabolic receptors—GLP‑1, GIP, and glucagon—to influence appetite, glycemic control, and energy expenditure simultaneously. Early studies suggest that this unified approach may deliver Read more…